Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04339660|
Recruitment Status : Recruiting
First Posted : April 9, 2020
Last Update Posted : April 9, 2020
|Condition or disease||Intervention/treatment||Phase|
|COVID-19||Biological: UC-MSCs Other: Placebo||Phase 1 Phase 2|
Since December 2019, novel coronavirus disease 2019 (COVID-19) in Wuhan has been fierce and spread rapidly. As of 24:00 on March 4, 2020, China has reported a total of 80567 confirmed cases, 5952 existing critically ill cases, and 3016 dead cases. The COVID-19 pneumonia has grown to be a global public health emergency since patients were first detected in Wuhan, China, in December 2019, which spread quickly to 26 countries worldwide and presented a serious threat to public health. It is mainly characterized by fever, dry cough, shortness of breath and breathing difficulties. Some patients may develop into rapid and deadly respiratory system injury with overwhelming inflammation in the lung. Currently, no specific drugs or vaccines are available to cure the patients with COVID-19 infection. Hence, there is a large unmet need for a safe and effective treatment for COVID-19 infected patients, especially the critically ill cases.
Recently, some clinical researches about the COVID-19 published in The Lancet and The New England Journal of Medicine suggested that massive inflammatory cell infiltration and inflammatory cytokines secretion were found in patients' lungs, alveolar epithelial cells and capillary endothelial cells were damaged, causing acute lung injury. Several reports demonstrated that the first step of the HCoV-19 pathogenesis is that the virus specifically recognizes the angiotensin I converting enzyme 2 receptor (ACE2) by its spike Protein. This receptor is abundant in lung and small intestinal tissues, but is also highly expressed in vascular endothelial cells and smooth muscle cells in almost all organs, including the nervous system and skeletal muscle. The main organ injured by the HCoV-19 is the lung. In fact, HCoV-19 can also involve the nervous system, digestive system, urinary system, blood system and other systems. Therefore, when the initial symptom is discomfort of other systems in the early stage, it is often easy to be misdiagnosed and delay treatment. Moreover, the HCoV-19 is a noncellular form consisting of RNA and protein, which cannot be copied independently. It needs to bind to cell surface receptors to enter the cell to complete the replication, and then be released again. Therefore, once the HCoV-19 enters the blood circulation, it can easily spread to all systems throughout the body, which may be the pathological mechanism that the HCoV-19 directly or indirectly causes neurological symptoms.
It seems that the key to cure the COVID-19 pneumonia is to inhibit the inflammatory response, resulting to reduce the damage of alveolar epithelial cells and endothelial cells and repair the function of the lung. MSCs, owing to their powerful immunomodulatory ability, may have beneficial effects on preventing or attenuating the cytokine storm.
Mesenchymal stem cells (MSCs) are widely used in basic research and clinical application. They are proved to migrate to damaged tissues, exert antiinflammatory and immunoregulatory functions, promote the regeneration of damaged tissues and inhibit tissue fibrosis. MSCs play a positive role mainly in two ways, namely immunomodulatory effects and differentiation abilities. MSCs can secrete many types of cytokines by paracrine secretion or make direct interactions with immune cells, leading to immunomodulation. Studies have shown that MSCs can significantly reduce acute lung injury in mice caused by H9N2 and H5N1 viruses by reducing the levels of proinflammatory cytokines and the recruitment of inflammatory cells into the lungs. Compared with MSCs from other sources, human umbilical cord-derived MSCs (UC-MSCs) have been widely applied to various diseases due to their convenient collection, no ethical controversy, low immunogenicity, and rapid proliferation rate.
Here we conducted an MSC transplantation pilot study to explore their therapeutic potential for COVID-19 pneumonia patients. To explore the effective treatment of COVID-19 pneumonia for the current prevention and control of novel coronavirus pneumonia to find a key and effective clinical treatment means, to fight against the epidemic.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Outcomes Assessor)|
|Official Title:||Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia|
|Actual Study Start Date :||February 1, 2020|
|Estimated Primary Completion Date :||June 30, 2020|
|Estimated Study Completion Date :||June 30, 2020|
Experimental: UC-MSCs treatment group
Participants will receive conventional and treatment with MSCs, MSCs were suspended in 100 mL of normal saline, and the total number of transplanted cells was calculated by 1*10E6 cells per kilogram of weight. This product is generally a course of treatment, a total of 1 time, depending on the condition of the need to be given again at an interval of 1 week.
1*10E6 UC-MSCs /kg body weight suspended in 100mL saline
Placebo Comparator: Control group
Participants will receive conventional treatment and Placebo intravenously.
100mL saline intravenously
- The immune function (TNF-α 、IL-1β、IL-6、TGF-β、IL-8、PCT、CRP) [ Time Frame: Observe the immune function of the participants within 4 weeks ]Improvement and recovery time of inflammatory and immune factors
- Blood oxygen saturation [ Time Frame: Monitor blood oxygen saturation of the participants within 4 weeks ]Evaluation of Pneumonia change
- Rate of mortality within 28-days [ Time Frame: At baseline, Day 1, Day 2, Day 7, Week 2, Week 3, Week 4 ]Marker for efficacy of treatment
- Size of lesion area by chest imaging [ Time Frame: At baseline, Day 1, Day 2, Day 7, Week 2, Week 3, Week 4 ]Evaluation of Pneumonia change
- CD4+ and CD8+ T cells count [ Time Frame: At baseline, Day 1, Day 2, Day 7, Week 2, Week 3, Week 4 ]Marker of Immunology and inflammation
- Peripheral blood count recovery time [ Time Frame: At baseline, Day 1, Day 2, Day 7, Week 2, Week 3, Week 4 ]Degree of infection
- Duration of respiratory symptoms (fever, dry cough, difficulty breathing, etc.) [ Time Frame: At baseline, Day 1, Day 2, Day 7, Week 2, Week 3, Week 4 ]Indirect response to lung function
- COVID-19 nucleic acid negative time [ Time Frame: At baseline, Day 1, Day 2, Day 7, Week 2, Week 3, Week 4 ]Clearance time of COVID-19 in participant
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04339660
|Contact: Yan Liu, MDemail@example.com|
|Contact: Yue Zhufirstname.lastname@example.org|
|Puren Hospital Affiliated to Wuhan University of Science and Technology||Recruiting|
|Wuhan, Hubei, China, 430081|
|Contact: Yan Liu, MD +8613387517458 email@example.com|